Anti-Interleukin-4, Neutralizing (IL-4)

Interleukin-4 (IL-4) is produced by T cells, NK T cells, gamma delta cells, and mast cells (1). Target cells include B cells, T cells, and macrophages (1). IL-4 induces differentiation of naive T cells into the Th2 phenotype. IL-4 also promotes B cell proliferation, antibody isotype switching, and expression of other Th2 cytokines including IL-5 and IL-9. IL-4-induced Th2 polarization is important in developing humoral immunity against extracellular pathogens (1) and is involved in the development of allergy and asthma (2). IL-4 binds to two distinct receptors, the type I receptor and type II receptor. The type I receptor is a heterodimer consisting of IL-4Ra chain and the common gamma chain, yc (3,4). The type II receptor, which is shared with IL-13, is a heterodimer of IL-4Ra and IL-13Ra1. Signaling initiated via type I receptor results in the activation of Jak1/Stat6, Jak3, and the PI3K/Akt pathways (3). The type II receptor activates the Jak1/Stat6 and the Tyk2/Stat3 pathways (3). Neutralizing antibodies can be used to inhibit normal biological function through their binding to biological molecules. These reagents can be used to determine the effects that a particular molecule has in biological systems. Human IL-4 Neutralizing has been shown to neutralize the proliferation of TF-1 cells in vitro with an ND50 in the range of 3-19ng/ml. , Applications: , Suitable for use in Neutralizing. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Endotoxin: <0.1 EU/ug of antibody. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O or PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.